Ignet

Gene Information

Gene symbol: SPATA19

Gene name: spermatogenesis associated 19

HGNC ID: 30614

Synonyms: FLJ25851, spergen1, SPAS1, CT132

Related Genes

#	Gene Symbol	Number of hits
1	CTLA4	1 hits
2	SH3GLB2	1 hits
3	TNFRSF25	1 hits

Related Sentences

#	PMID	Sentence
1	18303116	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
2	18303116	Using a combination of active tumor vaccination in the presence of CTL-associated antigen 4 (CTLA-4) in vivo blockade, we elicited tumor-specific T cells used to expression clone the first T cell-defined TRAMP tumor antigen, called Spas-1 (stimulator of prostatic adenocarcinoma specific T cells-1).
3	18303116	Spas-1 expression was increased in advanced primary TRAMP tumors.
4	18303116	We show that the immunodominant SPAS-1 epitope SNC9-H(8) arose from a point mutation in one allele of the gene in TRAMP tumor cells, and that immunization with dendritic cells pulsed with SNC9-H(8) peptide resulted in protection against TRAMP-C2 tumor challenge.
5	18303116	In humans, the Spas-1 ortholog SH3GLB2 has been reported to be overexpressed in prostate cancer metastases.
6	18303116	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
7	18303116	Using a combination of active tumor vaccination in the presence of CTL-associated antigen 4 (CTLA-4) in vivo blockade, we elicited tumor-specific T cells used to expression clone the first T cell-defined TRAMP tumor antigen, called Spas-1 (stimulator of prostatic adenocarcinoma specific T cells-1).
8	18303116	Spas-1 expression was increased in advanced primary TRAMP tumors.
9	18303116	We show that the immunodominant SPAS-1 epitope SNC9-H(8) arose from a point mutation in one allele of the gene in TRAMP tumor cells, and that immunization with dendritic cells pulsed with SNC9-H(8) peptide resulted in protection against TRAMP-C2 tumor challenge.
10	18303116	In humans, the Spas-1 ortholog SH3GLB2 has been reported to be overexpressed in prostate cancer metastases.
11	18303116	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
12	18303116	Using a combination of active tumor vaccination in the presence of CTL-associated antigen 4 (CTLA-4) in vivo blockade, we elicited tumor-specific T cells used to expression clone the first T cell-defined TRAMP tumor antigen, called Spas-1 (stimulator of prostatic adenocarcinoma specific T cells-1).
13	18303116	Spas-1 expression was increased in advanced primary TRAMP tumors.
14	18303116	We show that the immunodominant SPAS-1 epitope SNC9-H(8) arose from a point mutation in one allele of the gene in TRAMP tumor cells, and that immunization with dendritic cells pulsed with SNC9-H(8) peptide resulted in protection against TRAMP-C2 tumor challenge.
15	18303116	In humans, the Spas-1 ortholog SH3GLB2 has been reported to be overexpressed in prostate cancer metastases.
16	18303116	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
17	18303116	Using a combination of active tumor vaccination in the presence of CTL-associated antigen 4 (CTLA-4) in vivo blockade, we elicited tumor-specific T cells used to expression clone the first T cell-defined TRAMP tumor antigen, called Spas-1 (stimulator of prostatic adenocarcinoma specific T cells-1).
18	18303116	Spas-1 expression was increased in advanced primary TRAMP tumors.
19	18303116	We show that the immunodominant SPAS-1 epitope SNC9-H(8) arose from a point mutation in one allele of the gene in TRAMP tumor cells, and that immunization with dendritic cells pulsed with SNC9-H(8) peptide resulted in protection against TRAMP-C2 tumor challenge.
20	18303116	In humans, the Spas-1 ortholog SH3GLB2 has been reported to be overexpressed in prostate cancer metastases.
21	18303116	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
22	18303116	Using a combination of active tumor vaccination in the presence of CTL-associated antigen 4 (CTLA-4) in vivo blockade, we elicited tumor-specific T cells used to expression clone the first T cell-defined TRAMP tumor antigen, called Spas-1 (stimulator of prostatic adenocarcinoma specific T cells-1).
23	18303116	Spas-1 expression was increased in advanced primary TRAMP tumors.
24	18303116	We show that the immunodominant SPAS-1 epitope SNC9-H(8) arose from a point mutation in one allele of the gene in TRAMP tumor cells, and that immunization with dendritic cells pulsed with SNC9-H(8) peptide resulted in protection against TRAMP-C2 tumor challenge.
25	18303116	In humans, the Spas-1 ortholog SH3GLB2 has been reported to be overexpressed in prostate cancer metastases.